logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Lorlatinib for advanced ALK-positive non-small cell lung cancer – first line

< Back

Lorlatinib for advanced ALK-positive non-small cell lung cancer – first line

Drugs

Cancer and Palliative Care

December 2020


Lorlatinib is being investigated for the treatment of advanced anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC). NSCLC comprises the majority of lung cancers in the UK. Symptoms of lung cancer include a persistent cough, shortness of breath, coughing up blood, aches and pains in the chest or shoulder, loss of appetite, weight loss and fatigue. While current treatments exist for ALK-postive NSCLC, significant unmet medical need remains for more effective treatment options as treatment with current options inevitably leads to further progression of the disease over time.
Lorlatinib is administered orally in tablet form and works by acting as an inhibitor to tyrosine kinases which function as ‘on’/’off’ enzymes in cellular proteins. This prevents cancer cells from growing so can control the spread of the cells. If licensed, lorlatinib would offer an additional first-line treatment option for adult patients with ALK-positive NSCLC.

Innovation Observatory Voice 1

Informative

Stephanie Peace - Posted ago

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts